Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

16.82 -0.02 (-0.12%)

Streaming Delayed Price Updated: 9:35 AM EDT, Mar 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views ↗

July 29, 2025

Via Benzinga

Topics Earnings

Top movers analysis in the middle of the day on 2025-07-29: top gainers and losers in today's session. ↗

July 29, 2025

Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Sarepta Stock Soars After FDA Says It Can Resume Drug Shipments ↗

July 29, 2025

Sarepta stock soared after the FDA said the biotech company can resume shipments of a controversial gene therapy drug.

Via Investor's Business Daily

Topics Workforce

Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday ↗

July 29, 2025

Via Benzinga

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement ↗

July 23, 2025

Via Stocktwits

There are notable gap-ups and gap-downs in today's session. ↗

July 29, 2025

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

This Sarepta Therapeutics Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday ↗

July 29, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

July 29, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 29, 2025

Via Benzinga

Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

July 29, 2025

Via Benzinga

Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? ↗

July 29, 2025

Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys,...

Via Benzinga

Nvidia, Sarepta, HPE, Citi, EQT: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗

July 28, 2025

Sarepta stock’s after-hours jump came as the FDA notified the company that it could lift the voluntary pause on the shipments.

Via Stocktwits

Topics Artificial Intelligence Credit Cards

BitMine Immersion, Sarepta Therapeutics, CEA Industries, Super Micro Computer And AMD: Why These 5 Stocks Are On Investors' Radars Today ↗

July 28, 2025

U.S. markets closed mixed on Monday, with the Dow Jones Industrial Average slipping 0.1% to 44,837.56.

Via Benzinga

Topics Stocks

Why Sarepta Therapeutics Stock Surged Nearly 48% In After-Hours Trading Today ↗

July 28, 2025

The FDA concluded that a recent patient death in Brazil was unrelated to Sarepta’s Elevidys treatment, allowing the company to resume U.S. shipments for boys who can still walk.

Via Stocktwits

Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients ↗

July 28, 2025

Sarepta Therapeutics shares are halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys.

Via Benzinga

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys ↗

July 28, 2025

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.

Via Benzinga

Retail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy ↗

July 28, 2025

The update comes as Sarepta faces mounting regulatory scrutiny, including an ongoing FDA investigation and a recommendation from European regulators to reject approval of Elevidys.

Via Stocktwits

Topics Death

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗

July 25, 2025

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

Via Benzinga

Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback ↗

July 25, 2025

Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward.

Via Stocktwits

Topics Death

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe ↗

July 25, 2025

Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys.

Via Investor's Business Daily

Topics Death

Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 25, 2025

Via Benzinga

Friday's pre-market session: top gainers and losers ↗

July 25, 2025

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 25, 2025

Via Benzinga

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies. ↗

July 24, 2025

Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues.

Via Investor's Business Daily

Topics Death Workforce

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 24, 2025

Via Benzinga

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

July 24, 2025

Via Benzinga

Is This Stock a Buy After Soaring by 20% in 1 Day? ↗

July 24, 2025

Via The Motley Fool

Topics Death

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label ↗

July 23, 2025

Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and valuation cuts.

Via Benzinga

FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division ↗

July 22, 2025

George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and drug advertising rules.

Via Benzinga

Sarepta Tumbles On The 'Painful' Decision To Stop Selling Elevidys ↗

July 22, 2025

Sarepta stock toppled Tuesday after the company said it would voluntarily stop all shipments of Elevidys.

Via Investor's Business Daily

Topics Death ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

Headline News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today